ONCO · Onconetix, Inc.

The board composition changes at Onconetix, Inc. represent a significant governance transition: two long-standing directors, Oakley and Meier, have stepped down without any disclosed disagreement, indicating a planned and amicable refreshment rather than a reaction to performance or oversight concerns. Their departures vacated key committee seats—including the Chairmanship and multiple committee memberships—creating immediate structural gaps. The appointment of Sammy Dorf, already a sitting director, as Chairman provides continuity while centralizing leadership; his $20,000 annual stipend reflects formalized responsibilities distinct from standard director compensation. More notably, Josh Epstein brings highly specialized, multi-industry executive and board experience—spanning cannabis, mining tech, autonomous systems, and public company governance—with direct exposure to capital markets, M&A, and regulatory environments relevant to Onconetix’s likely growth stage. His assignment as chair of the Nominating and Corporate Governance Committee signals an intent to strengthen board oversight rigor, particularly around succession planning and ESG-aligned governance frameworks. As a Class II director serving only until the 2026 annual meeting, Epstein’s initial term is intentionally short, suggesting the Board may be evaluating broader governance strategy ahead of upcoming shareholder votes. Collectively, these moves enhance board expertise in high-velocity sectors while maintaining stability—potentially positioning the company for strategic initiatives requiring both operational discipline and capital markets readiness.